Surrozen, Inc. Common (SRZN)

Price$24.57

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)63.10%

Price vs S&P 500 (4W)-34.04%

VGM Score48.51

Market Capitalization$268.72M

All Metrics

Book Value / Share (Quarterly)$5.50

P/TBV (Annual)0.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.72%

Cash Flow / Share (Quarterly)$-2.93

Price vs S&P 500 (YTD)-8.98%

Net Profit Margin (TTM)-4571.14%

EPS (TTM)$-35.44

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-35.44

EPS (Annual)$-32.37

ROI (Annual)-113.46%

Cash / Share (Quarterly)$9.30

Revenue Growth QoQ (YoY)408.65%

ROA (Last FY)-245.15%

Revenue Growth TTM (YoY)-35.61%

EBITD / Share (TTM)$-4.59

ROE (5Y Avg)-72.54%

Operating Margin (TTM)-573.75%

Cash Flow / Share (Annual)$-3.11

P/B Ratio5.70x

P/B Ratio (Quarterly)1.63x

Net Income / Employee (Annual)$-5,500,600

EV / Revenue (TTM)21.59x

Net Interest Coverage (TTM)-2.40x

ROA (TTM)-329.25%

EPS Incl Extra (Annual)$-32.37

Current Ratio (Annual)9.22x

Quick Ratio (Quarterly)11.70x

3-Month Avg Trading Volume0.11M

52-Week Price Return184.69%

Revenue / Employee (TTM)$170,300

Tangible BV / Share (Quarterly)$1.80

P/S Ratio (Annual)77.29x

Asset Turnover (Annual)0.04x

52-Week High$35.00

EPS Excl Extra (Annual)$-32.37

CapEx CAGR (5Y)-31.84%

26-Week Price Return76.68%

Quick Ratio (Annual)9.01x

13-Week Price Return-19.07%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.91x

Enterprise Value$161.81M

Asset Turnover (TTM)0.07x

Revenue / Employee (Annual)$79,000

Pretax Margin (Annual)-6960.77%

Cash / Share (Annual)$9.13

3-Month Return Std Dev69.44%

Net Income / Employee (TTM)$-7,785,500

ROE (Last FY)-113.46%

EPS Basic Excl Extra (Annual)$-32.37

Receivables Turnover (TTM)1.96x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-35.44

Receivables Turnover (Annual)2.53x

ROI (TTM)58.23%

P/S Ratio (TTM)35.86x

Revenue / Share (Annual)$0.47

Tangible BV / Share (Annual)$2.53

Price vs S&P 500 (52W)156.53%

Year-to-Date Return2.41%

5-Day Price Return-12.53%

EPS Normalized (Annual)$-32.37

ROA (5Y Avg)-109.96%

Net Profit Margin (Annual)-6960.77%

Month-to-Date Return-11.69%

Cash Flow / Share (TTM)$-1.11

EBITD / Share (Annual)$-5.56

Operating Margin (Annual)-1210.58%

ROI (5Y Avg)-72.54%

EPS Basic Excl Extra (TTM)$-35.44

P/TBV (Quarterly)0.20x

P/B Ratio (Annual)0.51x

Pretax Margin (TTM)-4571.14%

Book Value / Share (Annual)$18.39

Price vs S&P 500 (13W)-29.74%

Beta0.51x

Revenue / Share (TTM)$0.68

ROE (TTM)58.23%

52-Week Low$7.80

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-11.65est. -1.11

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.25

4.22

4.20

4.18

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRZNSurrozen, Inc. Common	D	C	B	$24.57
AMGNAmgen Inc	C	C	C	$338.22
GILDGilead Sciences Inc	C	B	C	$128.99
ARGXargenx SE American Depositary Shares	D	A	B	$813.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$155.99
BIIBBiogen Inc. Common Stock	B	D	C	$195.96
BNTXBioNTech SE American Depositary Share	C	C	D	$88.45
MRNAModerna, Inc. Common Stock	C	B	C	$49.06
NBIXNeurocrine Biosciences Inc	C	B	B	$165.11
EXELExelixis Inc	C	B	B	$51.60
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$301.82

About

Surrozen is a clinical-stage biotechnology company developing selective Wnt pathway modulators to promote tissue repair and regeneration across multiple organs. The company's pipeline includes three product candidates designed to address significant unmet medical needs in regenerative medicine. By targeting the Wnt signaling pathway, Surrozen aims to unlock the body's natural tissue repair mechanisms.